Brooks G F, Barriere S L
Ann Intern Med. 1983 Apr;98(4):530-5. doi: 10.7326/0003-4819-98-4-530.
New beta-lactam antimicrobial agents with extended antibacterial activity for gram-negative bacilli are being developed and marketed. These drugs provide major advances, especially for treatment of serious infections caused by multiresistant organisms. Several of the drugs have been marketed and many more will be available. Some of these drugs are considerably more costly than the older beta-lactams. The large number of new antimicrobial drugs coupled with their high costs pose complex problems for physicians, microbiology laboratories, and pharmacists. Community hospitals, large general hospitals, and tertiary care hospitals have different needs for patient care and will need different formats for unbiased education, susceptibility testing, pharmacy stocking, and controlling or monitoring for inappropriate use.
具有针对革兰氏阴性杆菌的扩展抗菌活性的新型β-内酰胺类抗菌药物正在研发并上市。这些药物取得了重大进展，特别是在治疗由多重耐药菌引起的严重感染方面。其中几种药物已经上市，还有更多药物即将面市。这些药物中的一些比旧的β-内酰胺类药物成本要高得多。大量新型抗菌药物及其高昂成本给医生、微生物实验室和药剂师带来了复杂的问题。社区医院、大型综合医院和三级护理医院对患者护理有不同需求，并且在无偏见教育、药敏试验、药房库存以及控制或监测不当使用方面也需要不同的形式。
